Delivery Order SPE2DB20D7059-SPE2DB24FPZP1

Award Date 2/21/24
Potential Completion Date 2/22/24
Potential Value $3.5K
Ultimate Awardee
Cencora, Inc.
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the supply of 1 mg vials of the pharmaceutical drug remifentanil, with a firm fixed price ceiling value of $3,072.30 and a completion date of June 27, 2024. Amerisourcebergen, a major pharmaceutical distribution company, holds a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 with DLA...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $5,317.05 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide 1 mg vials of the pharmaceutical drug remifentanil. The contract has a completion date of February 1, 2024 and was awarded on January 31, 2024. AmerisourceBergen Drug Corp, as the prime contractor, will deliver the pharmaceutical product to support military treatment programs and facilities. This delivery...
This is a $9,081.50 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 2 mg vials of the drug remifentanil, a potent opioid analgesic used in anesthesia and pain management. This delivery order contract is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Remifentanil 1 mg vials. The contract has a ceiling value of $1,755.60 and a period of performance through October 31, 2024. It is a firm fixed-price delivery order contract, with no set-aside designation. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999, which...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of Remifentanil 1 mg vials, a specialty medication. The contract is a firm-fixed-price delivery order with a ceiling value of $3,544.70 and a performance period ending on September 20, 2024. The contract is not designated as a set-aside. Amerisourcebergen Drug Corp's Corporate Office division will be the primary...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,637.53 firm fixed-price contract is for the delivery of remifentanil 2 mg vials, a specialty medication used for pain management. The delivery order is part of a larger $999,999,999 indefinite delivery contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a primary vehicle for...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical company Amerisourcebergen Corporation. The $2,633.40 fixed-price contract is for the supply of Remifentanil 2 mg vials, a specialty pharmaceutical product used in military treatment facilities. The contract has a period of performance through March 22, 2024. Amerisourcebergen Drug Corp holds an Indefinite Delivery Contract...
This federal contract award, valued at $3,640.60, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Remifentanil 2 mg vials, a specialized medication. This award is a delivery order placed against AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $11,652.49 firm fixed-price contract is for the delivery of 2 mg vials of the drug remifentanil, a potent synthetic opioid analgesic. The contract has a period of performance through May 2024 and was not set aside for any specific business category. AmerisourceBergen holds a $999,999,999 Indefinite Delivery...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, with a ceiling value of $5,266.80. The contract is for the supply of REMIFENTANIL 1 MG VIALS, a pharmaceutical product used for anesthesia and pain management. The award has a firm-fixed price and is not associated with any set-aside designations. AmerisourceBergen Drug Corp, through its Corporate Office Division, has a significant Indefinite Delivery...
  • SPE2DB20D7059
    Indefinite Delivery Contract
  • SPE2DB20D7059-SPE2DB24FPZP1
    Delivery Order

This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a wholly-owned subsidiary of the parent company Cencora, Inc. The contract provides for the delivery of 1 mg vials of the medication Remifentanil, with a potential value of $3,544.70 and a completion date of February 22, 2024. The contract is not a set-aside. Amerisourcebergen Drug Corp serves as a prime contractor providing a wide range of pharmaceutical products and medical supplies to U.S. government agencies, including the Department of Defense, through various indefinite delivery contracts (IDCs) with the DLA. This specific delivery order is issued under an IDC with a potential value of up to $999,999,999.00 and a performance period through December 31, 2025, which enables the company to deliver a comprehensive range of medications and healthcare materials to military treatment programs and facilities worldwide.

Generated 5/22/24, 10:01 AM